Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Century Therapeutics (IPSC) FCF Margin (2022 - 2025)

Historic FCF Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 32.15%.

  • Century Therapeutics' FCF Margin rose 35686700.0% to 32.15% in Q1 2025 from the same period last year, while for Sep 2025 it was 99.71%, marking a year-over-year increase of 41433400.0%. This contributed to the annual value of 1673.84% for FY2024, which is 28936800.0% up from last year.
  • According to the latest figures from Q1 2025, Century Therapeutics' FCF Margin is 32.15%, which was up 35686700.0% from 580.47% recorded in Q4 2024.
  • Century Therapeutics' FCF Margin's 5-year high stood at 7815.31% during Q1 2022, with a 5-year trough of 23989.9% in Q2 2023.
  • Its 4-year average for FCF Margin is 4679.24%, with a median of 3579.38% in 2024.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -214101700bps in 2023, then surged by 204105200bps in 2024.
  • Century Therapeutics' FCF Margin (Quarter) stood at 5599.81% in 2022, then crashed by -81bps to 10152.99% in 2023, then surged by 94bps to 580.47% in 2024, then surged by 94bps to 32.15% in 2025.
  • Its FCF Margin stands at 32.15% for Q1 2025, versus 580.47% for Q4 2024 and 3581.8% for Q3 2024.